CMS and Opioids: The Role for Non-Drug Reimbursements
This article was originally published in RPM Report
The Centers for Medicare and Medicaid Services proposed Part D rules to give plans some responsibility for monitoring opioid abuse. But providers at a Senate Finance Hearing think CMS reimbursements beyond drugs can have a role in screening abuse – and in treating pain to begin with.
You may also be interested in...
The 21st Century Cures legislation provides CMS with new authority to limit Part D beneficiary access to pharmacies and providers when there is concern about misuse or abuse of prescriptions. Now legislators want CMS to do even more.
The HHS Inspector General says CMS is doing a lot to prevent waste, fraud and abuse in Part D. But the IG report also identifies some tools CMS isn’t using – and says it doesn’t want.
HHS is declaring a priority of reducing the burden of adverse events associated with three large classes of drugs: opioids, antidiabetics, and anticoagulants. And, at least in its draft action plan, FDA is not the central actor.